MX2007015430A - Regimen de dosificacion para prasugrel. - Google Patents
Regimen de dosificacion para prasugrel.Info
- Publication number
- MX2007015430A MX2007015430A MX2007015430A MX2007015430A MX2007015430A MX 2007015430 A MX2007015430 A MX 2007015430A MX 2007015430 A MX2007015430 A MX 2007015430A MX 2007015430 A MX2007015430 A MX 2007015430A MX 2007015430 A MX2007015430 A MX 2007015430A
- Authority
- MX
- Mexico
- Prior art keywords
- prasugrel
- compound
- dose
- formula
- equivalent
- Prior art date
Links
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 239000005465 B01AC22 - Prasugrel Substances 0.000 title claims abstract description 78
- 229960004197 prasugrel Drugs 0.000 title claims abstract description 78
- 238000012423 maintenance Methods 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 208000019553 vascular disease Diseases 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 41
- JALHGCPDPSNJNY-UHFFFAOYSA-N [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4h-thieno[3,2-c]pyridin-2-yl] acetate;hydron;chloride Chemical compound Cl.C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 JALHGCPDPSNJNY-UHFFFAOYSA-N 0.000 claims description 23
- 229960004947 prasugrel hydrochloride Drugs 0.000 claims description 23
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 21
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 17
- 208000007536 Thrombosis Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 10
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 10
- 208000005189 Embolism Diseases 0.000 claims description 9
- 208000001435 Thromboembolism Diseases 0.000 claims description 9
- 150000003840 hydrochlorides Chemical class 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 26
- 229960003009 clopidogrel Drugs 0.000 description 26
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 26
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 15
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 12
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229940125670 thienopyridine Drugs 0.000 description 5
- 239000002175 thienopyridine Substances 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000010102 embolization Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940047170 clopidogrel 300 mg Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000007214 atherothrombosis Effects 0.000 description 2
- 238000011970 concomitant therapy Methods 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- WJFYLCXWEXZNHU-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridine Chemical class N1C=CC=C2SCCC21 WJFYLCXWEXZNHU-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 206010007513 Cardiac aneurysm Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100001347 Mus musculus Akt1s1 gene Proteins 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940066015 clopidogrel 75 mg Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- -1 maleate salt Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229940101750 prasugrel 10 mg Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69174005P | 2005-06-17 | 2005-06-17 | |
| PCT/US2006/023006 WO2006138317A2 (en) | 2005-06-17 | 2006-06-13 | Dosage regimen for prasugrel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007015430A true MX2007015430A (es) | 2008-02-21 |
Family
ID=37571073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007015430A MX2007015430A (es) | 2005-06-17 | 2006-06-13 | Regimen de dosificacion para prasugrel. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090156632A1 (enExample) |
| EP (1) | EP1893205A4 (enExample) |
| JP (1) | JP2008543853A (enExample) |
| KR (1) | KR20080016647A (enExample) |
| CN (1) | CN101198329A (enExample) |
| AU (1) | AU2006259538A1 (enExample) |
| BR (1) | BRPI0612624A2 (enExample) |
| CA (1) | CA2612315A1 (enExample) |
| EA (1) | EA200800075A1 (enExample) |
| EC (1) | ECSP078014A (enExample) |
| GT (1) | GT200600263A (enExample) |
| IL (1) | IL187486A0 (enExample) |
| MA (1) | MA29722B1 (enExample) |
| MX (1) | MX2007015430A (enExample) |
| NO (1) | NO20080244L (enExample) |
| TN (1) | TNSN07474A1 (enExample) |
| WO (1) | WO2006138317A2 (enExample) |
| ZA (1) | ZA200710769B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008072532A1 (ja) * | 2006-12-07 | 2010-03-25 | 第一三共株式会社 | 貯蔵安定性が改善された医薬組成物 |
| TWI482641B (zh) | 2006-12-07 | 2015-05-01 | Daiichi Sankyo Co Ltd | 含有低取代度羥丙基纖維素之醫藥組成物 |
| CN101686681B (zh) | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| PL3100728T3 (pl) | 2009-05-13 | 2020-05-18 | Cydex Pharmaceuticals, Inc. | Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania |
| US10376532B2 (en) * | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| TR201006802A1 (tr) * | 2010-08-17 | 2012-03-21 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Prasugrelin oral yolla dağılan formülasyonları. |
| EP2409685A3 (en) | 2010-07-19 | 2012-02-01 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-disintegrating formulations of prasugrel |
| EP3106151A1 (en) | 2015-06-19 | 2016-12-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical compositions of prasugrel hydrobromide |
| WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
| US6544981B2 (en) * | 2000-06-09 | 2003-04-08 | Bristol-Myers Squibb Company | Lactam inhibitors of factor Xa and method |
| KR20080021152A (ko) * | 2000-07-06 | 2008-03-06 | 다이이찌 산쿄 가부시키가이샤 | 히드로피리딘 유도체 산부가염 |
| JP4001199B2 (ja) * | 2000-07-06 | 2007-10-31 | 第一三共株式会社 | ヒドロピリジン誘導体酸付加塩 |
| JP4874482B2 (ja) * | 2000-12-25 | 2012-02-15 | 第一三共株式会社 | アスピリンを含有する医薬組成物 |
| CZ297570B6 (cs) * | 2000-12-25 | 2007-02-07 | Sankyo Company, Limited | Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití |
| EP1660183A2 (en) * | 2003-05-05 | 2006-05-31 | Eli Lilly and Company | Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4) |
-
2006
- 2006-06-13 KR KR1020077029366A patent/KR20080016647A/ko not_active Ceased
- 2006-06-13 US US11/916,817 patent/US20090156632A1/en not_active Abandoned
- 2006-06-13 CN CNA2006800217943A patent/CN101198329A/zh active Pending
- 2006-06-13 CA CA002612315A patent/CA2612315A1/en not_active Abandoned
- 2006-06-13 AU AU2006259538A patent/AU2006259538A1/en not_active Abandoned
- 2006-06-13 WO PCT/US2006/023006 patent/WO2006138317A2/en not_active Ceased
- 2006-06-13 EP EP06773053A patent/EP1893205A4/en not_active Withdrawn
- 2006-06-13 EA EA200800075A patent/EA200800075A1/ru unknown
- 2006-06-13 JP JP2008517022A patent/JP2008543853A/ja active Pending
- 2006-06-13 BR BRPI0612624A patent/BRPI0612624A2/pt not_active IP Right Cessation
- 2006-06-13 MX MX2007015430A patent/MX2007015430A/es unknown
- 2006-06-16 GT GT200600263A patent/GT200600263A/es unknown
-
2007
- 2007-11-19 IL IL187486A patent/IL187486A0/en unknown
- 2007-12-11 ZA ZA200710769A patent/ZA200710769B/xx unknown
- 2007-12-14 EC EC2007008014A patent/ECSP078014A/es unknown
- 2007-12-14 TN TNP2007000474A patent/TNSN07474A1/en unknown
-
2008
- 2008-01-14 NO NO20080244A patent/NO20080244L/no not_active Application Discontinuation
- 2008-01-16 MA MA30577A patent/MA29722B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008543853A (ja) | 2008-12-04 |
| MA29722B1 (fr) | 2008-09-01 |
| GT200600263A (es) | 2007-02-23 |
| US20090156632A1 (en) | 2009-06-18 |
| BRPI0612624A2 (pt) | 2016-11-29 |
| NO20080244L (no) | 2008-01-14 |
| EA200800075A1 (ru) | 2008-04-28 |
| CN101198329A (zh) | 2008-06-11 |
| WO2006138317A2 (en) | 2006-12-28 |
| AU2006259538A1 (en) | 2006-12-28 |
| WO2006138317A3 (en) | 2007-05-03 |
| KR20080016647A (ko) | 2008-02-21 |
| ECSP078014A (es) | 2008-01-23 |
| EP1893205A2 (en) | 2008-03-05 |
| ZA200710769B (en) | 2009-09-30 |
| EP1893205A4 (en) | 2010-06-30 |
| IL187486A0 (en) | 2008-06-05 |
| TNSN07474A1 (en) | 2009-03-17 |
| CA2612315A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1896019B1 (en) | Formulation of a thienopyridine platelet aggregation inhibitor | |
| US8569325B2 (en) | Method of treatment with coadministration of aspirin and prasugrel | |
| EA015122B1 (ru) | Фармацевтическая композиция и ее применение для лечения тромбоза | |
| WO2004098713A2 (en) | Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4) | |
| WO2006138317A2 (en) | Dosage regimen for prasugrel | |
| Turpie | Warfarin replacements: mechanisms underlying emerging agents | |
| US20250195549A1 (en) | New use | |
| CA2828238A1 (en) | Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib | |
| WO2011052500A1 (ja) | ワックス安定製剤 | |
| EP4593833A1 (en) | Fractalkine receptor antagonists for use in the prevention of thrombus formation and/or growth | |
| Schmitt | ICD and PM Implantation Procedure: Relevant Periprocedural Issues | |
| HK1056118B (en) | Medicinal compositions containing aspirin | |
| HK1116422B (en) | Formulation of a thienopyridine platelet aggregation inhibitor | |
| HK1117386A (en) | Method of treating liver cancer |